

New insights into the regulatory pathways associated with the activation of the stringent response in bacterial resistance to the PBP2-targeted antibiotics, mecillinam and OP0595/RG6080

M. Doumith^{1*}, S. Mushtaq¹, D. M. Livermore^{1,2} and N. Woodford¹

¹National Infection Service, Public Health England, London NW9 5EQ, UK; ²Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK

*Corresponding author. Tel: +44-(0)20-8327-6834; E-mail: michel.doumith@phe.gov.uk

Received 15 March 2016; returned 23 April 2016; revised 29 April 2016; accepted 13 May 2016

Objectives: The diazabicyclooctane β -lactamase inhibitor OP0595 (RG6080) also acts as an antibiotic, targeting PBP2 in Enterobacteriaceae, but this activity is vulnerable to mutational resistance. We used WGS to investigate the basis of this resistance.

Methods: Twenty OP0595-selected mutants, comprising four derived from each of five different *Escherichia coli* strains, were sequenced on Illumina HiSeq. Reads from each mutant were mapped to the assembled genome of the corresponding parent. A variant-calling file generated with Samtools was parsed to determine genetic alterations.

Results: Besides OP0595, the mutants consistently showed decreased susceptibility to mecillinam, which likewise targets PBP2, and grew as stable round forms in the presence of subinhibitory concentrations of OP0595. Among the 20 mutants, 18 had alterations in genes encoding tRNA synthase and modification functions liable to induce expression of the RpoS sigma factor through activation of the stringent response or had mutations suppressing inactivators of RpoS or the stringent response signal-degrading enzyme, SpoT. TolB was inactivated in one mutant: this activates RcsBC regulation and was previously associated with mecillinam resistance. The mechanism of resistance remained unidentified in one mutant. Both the RpoS and RcsBC systems regulate genes of cell division, including *ftsAQZ* that can compensate for loss or inhibition of PBP2, allowing survival of the challenged bacteria as stable round forms, as seen.

Conclusions: WGS identified the global stringent response signal, entailing induction of RpoS, as the main mediator of mutational resistance to OP0595 in *E. coli*.

Introduction

Production of β -lactamases is the prevalent mode of resistance to β -lactam antibiotics in Gram-negative bacteria. To counter this, several new β -lactamase inhibitors are under clinical development, including several diazabicyclooctanes, such as OP0595 (RG6080).¹

OP0595 inhibits class A and C serine β -lactamases and also acts as an antibiotic, targeting PBP2 of Enterobacteriaceae as does mecillinam. Furthermore, and independent of β -lactamase inhibition, OP0595 acts as an 'enhancer', synergizing β -lactams that bind to PBP3.¹ Its antimicrobial activity is vulnerable to high-frequency mutational resistance and we used WGS to investigate its genetic basis.^{1,2}

Materials and methods

Selection and characterization of OP0595-resistant mutants

OP0595-resistant mutants from five different *Escherichia coli* strains were selected by applying overnight broth culture onto Mueller–Hinton agar containing OP0595 at 16 mg/L.² Parent and mutant cell shapes were investigated under microscopy after 2 h of incubation in broth supplemented with OP0595 at multiples of MICs for the parent strains. Images were taken after bacterial staining with 1.5% phosphotungstic acid, using a JEM-1400 transmission electron microscope (JEOL, Peabody, MA, USA) fitted with an AMTX XR60 camera. Susceptibility testing was performed by agar dilutions according to BSAC guidelines.³

Sequencing and bioinformatics

Parent and mutant DNA were extracted on the QIASymphony automated platform (QIAGEN, Hilden, Germany) used according to the manufacturer's instructions. Paired-end reads of 2×100 nucleotides with >30× depth of coverage were generated for each sequenced DNA on an Illumina HiSeq instrument using the Nextera XT DNA sample preparation kit (Illumina, San Diego, CA, USA). Reads were trimmed to remove low-quality nucleotides using Trimmomatic 0.32 (<http://www.usadellab.org/cms/?page=trimmomatic>), specifying a sliding window of 4 with average Phred quality of 30 and 50 as the minimum read length to be conserved. Trimmed reads for parents and mutants were assembled into contigs with VelvetOptimiser 2.1.9 software (<http://bioinformatics.net.au/software.velvetoptimiser.shtml>), using *k*-mer values from 55 to 75. Only contigs ≥300 bp were used in further analysis. Reads from the four mutants of each set were individually mapped to the assembled contigs of the corresponding parent, using Bowtie2 (<http://bowtie-bio.sourceforge.net/bowtie2>) in a global alignment mode to generate a sequence alignment/map file, which was used to generate a variant-calling file (VCF) using the Samtools 0.1.18 algorithm (<http://samtools.sourceforge.net>) with default settings. Base polymorphisms and small indels were detected using an in-house Python script, which parsed the VCF file line by line to determine the base calls at each nucleotide position, with filtering based on the read coverage (≥5 reads), frequency of polymorphic bases (≥80%) and overall quality of the variant call (base mapping ≥25 Phred score). Potential large deletions or insertions were checked in the VCF by filtering

for read coverage (≤2) and the frequency of the read-start and -end information (≥50%). All detected base polymorphisms were manually confirmed on Tablet 1.14 (<https://ics.hutton.ac.uk/tablet/>) and suspect genomes carrying large genetic alterations were visualized using Mauve 2.3.1 software (<http://darlinglab.org/mauve/mauve.html>). The Illumina sequences generated in this study are deposited and available in the European Nucleotide Archive under study accession number PRJEB12745 (<http://www.ebi.ac.uk/ena>).

Results and discussion

MICs of OP0595 for the 20 mutants exceeded 32 mg/L, compared with 0.5–1 mg/L for their susceptible parent strains.² The mutants exhibited at least an 8-fold increase in resistance to mecillinam, which also solely targets PBP2, whereas MIC shifts of β-lactam antibiotics targeting other PBPs were variable and lacked any consistent trend.² To elucidate these resistance traits, parent and mutant genomes were sequenced and various alterations were identified in multiple regions of the chromosome. These ranged from single nucleotide substitutions to deletions or insertions of 2–3767 nucleotides. Based on the annotation of *E. coli* published genomes, we located alterations to coding fractions of the genome that were inferred to result in amino acid changes or loss in 19 of the 20 mutants, including 8 cases where replacements generated a

Table 1. Gene alterations associated with OP0595 resistance from this study

Isolates	Alterations		Genes	Functions
	nucleotides	amino acids ^a		
EC-1	M-1 T→C	R337C	<i>rpoC</i>	DNA-directed RNA polymerase
	M-2 del-TGTTGCG	L136*	<i>cca</i>	tRNA nucleotidyl transferase
	M-3 A→G	G144S	<i>hemL</i>	glutamate-1-semialdehyde-2,1-aminomutase
	M-4 A→G	G474S	<i>lysS</i>	lysine tRNA ligase
EC-2	M-1 A→C	V54G	<i>ribE</i>	riboflavin synthase β chain
	M-1 G→A	W91*	<i>rlm</i>	50S rRNA methyltransferase
	M-2 C→T	T36A	<i>alaS</i>	alanyl-tRNA synthetase
	M-3 G→A	Q192*	<i>tolB</i>	periplasmic protein, TonB-independent uptake of group A colicins
	M-4 G→A	Q371*	<i>cydA</i>	cytochrome d ubiquinol oxidase, subunit I
EC-3	M-1 del AG	L351*	<i>arcB</i>	aerobic respiration control sensor protein
	M-2 C→A	E335*	<i>mnmA</i>	tRNA (Gln, Lys, Glu) 5-methylaminomethyl-2-thiouridylase methyltransferase
	M-3 del 3767 bp		<i>lysS</i>	lysine tRNA ligase—isopentenyl-diphosphate isomerase ^b —hypothetical ^b —purine permease ^b
	M-4 C→G	P1019A	<i>bcsC</i>	cellulose synthase subunit
EC-4	M-1 C→T	P555S	<i>aspS</i>	aspartyl-tRNA synthetase
	M-2 IS insertion		intergenic	225 bp upstream <i>arcA</i> —potential regulatory region
	M-3 A→T	V74E	<i>spoT</i>	guanosine-3',5'-bis(diphosphate)
	M-4 G→T	E329*	<i>cydA</i>	cytochrome d ubiquinol oxidase, subunit I
EC-5	M-1 T→C	F197L	<i>aspS</i>	aspartyl-tRNA synthetase
	M-2 ins-ACGCGTATT	133-LRV	<i>cca</i>	tRNA nucleotidyl transferase
	M-3 ins-TAC	153Y	<i>ileS</i>	isoleucyl-tRNA ligase
	M-4 del-TGATGTCC	I152*	<i>arcA</i>	DNA-binding response regulator in two-component regulatory system with ArcB

ins, insertion; del, deletion.

Genes shown in bold font encode proteins involved in the synthesis or modification of aminoacyl tRNAs. All annotations are in relation to the published *E. coli* MG1665 genome (GenBank: U00096).

^aAn asterisk indicates a stop codon.

^bGenes in the deleted DNA fragment that are unlikely to be associated with resistance.

premature translation-termination codon (Table 1). Only one mutant (EC-4 M-2) had an alteration in a non-coding intergenic region, involving an IS 225 bp upstream from the transcription start of the global two-component system *arcA* gene (Table 1).

Sixteen different altered genes were detected among the 20 OP0595-resistant mutants. These did not include *pbp2*, which encodes the OP0595 target, PBP2. Rather, seven genes, namely *lysS*, *alaS*, *aspS*, *ileS*, *cca*, *hemL* and *mnmA*, variously altered in 10/20 mutants, encoded aminoacyl tRNA synthesis and modification functions (Table 1). Alterations in the coding sequences of *alaS*, *aspS* and other (e.g. *argS*, *thrS*, *leuS* and *gltX*) tRNA synthetase genes have previously been associated with mecillinam resistance and are known to result in increased intracellular levels of the stringent response signal mediator guanosine-3',5'-bisdiphosphate (ppGpp).^{4–6} The stringent response is a widespread global regulatory system, activated in response to various stresses. Production of ppGpp depends on the ribosome-associated protein RelA, which is activated under amino acid

limitation and when uncharged tRNAs bind to the ribosomal A site.^{7,8} Degradation of ppGpp, upon return of favourable conditions, is catalysed by SpoT, a bifunctional enzyme that can also synthesize ppGpp in response to carbon, fatty acid and iron limitation, although less efficiently than RelA.^{7,8} ppGpp primarily regulates gene transcription and is required for the expression of the sigma factor RpoS, which is known to regulate multiple genes and, in particular, those associated with cell division at stationary phase, including the *ftsAQZ* operon, activation of which may be the effector mechanism for resistance to PBP2-targeted agents.^{9,10} The alterations identified in genes encoding aminoacyl tRNA synthesis and modification functions in these 10 OP0595-resistant mutants (Table 1) would be expected to decrease the aminoacyl tRNA levels in the cell, mimicking the amino acid starvation stress conditions that activate RelA to produce ppGpp.

Five of the remaining 10 mutants had alterations in the coding sequence or potential regulatory region of the global two-component systems *arcA* or the cytochrome d-ubiquinol oxidase




Figure 1. Parents and their OP0595-selected mutants after 2 h of incubation with OP0595 at 2× MIC for the parent strains (1–2 mg/L); these concentrations are $\leq 0.0625\times$ MIC for the mutants. The distinction is that the mutants conserve their round shapes in the absence of OP0595 and can survive the inhibition of PBP2, whereas their parents cannot.

subunit *cydA* (Table 1). Inactivation of either *arcA* or *cydA* has been shown to increase the expression of the sigma regulator factor *rpoS*.^{11,12} Of the final five mutants, one had an alteration in the ppGpp-degrading enzyme SpoT and one had the 50S rRNA methyltransferase Rlm inactivated, together with a possibly insignificant mutation in *ribE*. Mutations in rRNA methyltransferase result in a slow-growing phenotype, which also may induce the stringent response.¹³ Another mutant had alterations in the RNA polymerase subunit RpoC, which interacts with RpoS and, although the mechanism of linkage is uncertain, alteration of the second subunit of the RNA polymerase, RpoB, was previously associated with mecillinam resistance.¹⁴ Another mutant had inactivation of TolB, a periplasmic component of the Tol-Pal system involved in maintaining outer membrane integrity.¹⁵ Release of periplasmic components into the extracellular medium of *tol-pal* mutants leads to osmosensitivity and activates the sensor protein RcsC, which, with RcsB, regulates expression of *ftsAQZ* independently from the RpoS pathway.^{16–20} Alterations of RcsBC regulation have been associated with mecillinam resistance in *E. coli* mutants.²¹ The origin of resistance remained unclear in one mutant (EC-3 M-4), which had alteration only in *bcsC*, which encodes a cellulose synthase.

Induction of either the RpoS or RcsBC regulatory pathways stimulates expression of FtsZ, the possible mediator. Of the six promoters identified upstream of *ftsZ* in *E. coli*, *ftsQ1p* is recognized by RpoS, whereas *ftsA1p* is stimulated by the two-component system RcsBC.^{16,22–25} FtsZ is widely conserved among prokaryotes and shares a common ancestor with eukaryotic tubulin.²⁶ It can modulate membrane plasticity and overexpression in *E. coli* has been reported to allow stable growth as a round-shaped cell to compensate for PBP2 loss.²⁷ All the OP0595-resistant mutants exhibited spherical forms after 2 h of incubation in broth supplemented with sub-MICs of OP0595 (Figure 1), an observation in keeping with previous data for mecillinam and with the view that resistance to these agents entails compensation for inhibition of PBP2, not modification or shielding of this target.²⁸

Combining WGS with published experimental data of altered genes in OP0595-resistant mutants is sufficient to elucidate the underlying molecular mechanisms (Figure 2). Briefly, the main mechanism of resistance to OP0595 is activation of RpoS either: (i) through stimulation of the stress stringent response; or (ii) by

inactivation of RpoS suppressors, such as ArcAB and CydA (Figure 2). Activation of the RcsBC regulatory system, previously identified in mecillinam-resistant mutants, can also potentially lead to OP0595 resistance.^{5,21} Both RpoS and RcsB regulate genes encoding cell division functions, specifically *ftsAQZ*, that can compensate for PBP2 loss or inhibition, allowing survival of the challenged bacteria as stable round forms. This hypothesis is in keeping with the observed morphological effects and with the fact that OP0595 continues to act as a β -lactamase inhibitor and as a β -lactamase inhibition-independent synergist ('enhancer') of PBP3-targeted antibiotics against Enterobacteriaceae that are resistant to its direct antibacterial activity.^{1,2}

Acknowledgements

We would like to thank Matthew Hannah for his assistance with electronic microscopy.

Funding

The study was commissioned and funded by Meiji Seika Pharma.

Transparency declarations

D. M. L. has been involved in Advisory Boards or *ad hoc* consultancy for Accelerate, Achaogen, Adenium, Alere, Allegra, Altermune, Astellas, AstraZeneca, Auspherix, Basilea, Bayer, BioVersys, Cubist, Curetis, Cycle, Discuva, Forest, GSK, Meiji, Pfizer, Roche, Shionogi, Tetrphase, VenatoRx and Wockhardt, has given paid lectures for AOP Orphan, Astellas, AstraZeneca, Bruker, Curetis, Merck, Pfizer and Leo, and has shareholdings in Dechra, GSK, Merck, PerkinElmer and Pfizer amounting to <10% of portfolio value. All other authors: none to declare.

References

- 1 Morinaka A, Tsutsumi Y, Yamada M *et al*. OP0595, a new diazabicyclooctane: mode of action as a serine β -lactamase inhibitor, antibiotic and β -lactam 'enhancer'. *J Antimicrob Chemother* 2015; **70**: 2779–86.
- 2 Livermore DM, Warner M, Mushtaq S *et al*. Interactions of OP0595—a novel triple-action diazabicyclooctane—with β -lactams against OP0595-resistant Enterobacteriaceae mutants. *Antimicrob Agents Chemother* 2015; **60**: 554–60.
- 3 Andrews JM. Determination of minimum inhibitory concentrations. *J Antimicrob Chemother* 2001; **48** Suppl 1: 5–16.
- 4 Boulloc P, Vinella D, D'Ari R. Leucine and serine induce mecillinam resistance in *Escherichia coli*. *Mol Gen Genet* 1992; **235**: 242–6.
- 5 Thulin E, Sundqvist M, Andersson DI. Amdinocillin (mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of *Escherichia coli*. *Antimicrob Agents Chemother* 2015; **59**: 1718–27.
- 6 Vinella D, D'Ari R, Jaffe A *et al*. Penicillin binding protein 2 is dispensable in *Escherichia coli* when ppGpp synthesis is induced. *EMBO J* 1992; **11**: 1493–501.
- 7 Magnusson LU, Farewell A, Nystrom T. ppGpp: a global regulator in *Escherichia coli*. *Trends Microbiol* 2005; **13**: 236–42.
- 8 Hauryliuk V, Atkinson GC, Murakami KS *et al*. Recent functional insights into the role of (p)ppGpp in bacterial physiology. *Nat Rev Microbiol* 2015; **13**: 298–309.
- 9 Cam K, Cuzange A, Bouche JP. Sigma S-dependent overexpression of *ftsZ* in an *Escherichia coli* K-12 *rpoB* mutant that is resistant to the division inhibitors DicB and DicF RNA. *Mol Gen Genet* 1995; **248**: 190–4.




Figure 2. Proposed mechanism(s) of resistance to the antimicrobial activity of OP0595.

- 10 Loewen PC, Hu B, Strutinsky J et al. Regulation in the *rpoS* regulon of *Escherichia coli*. *Can J Microbiol* 1998; **44**: 707–17.
- 11 Mika F, Hengge R. A two-component phosphotransfer network involving ArcB, ArcA, and RssB coordinates synthesis and proteolysis of σ^S (RpoS) in *E. coli*. *Genes Dev* 2005; **19**: 2770–81.
- 12 Sevcik M, Sebkova A, Volf J et al. Transcription of *arcA* and *rpoS* during growth of *Salmonella typhimurium* under aerobic and microaerobic conditions. *Microbiology* 2001; **147**: 701–8.
- 13 Gustafsson C, Persson BC. Identification of the *rrmA* gene encoding the 23S rRNA m¹G745 methyltransferase in *Escherichia coli* and characterization of an m¹G745-deficient mutant. *J Bacteriol* 1998; **180**: 359–65.
- 14 Vinella D, D'Ari R. Thermoinducible filamentation in *Escherichia coli* due to an altered RNA polymerase β subunit is suppressed by high levels of ppGpp. *J Bacteriol* 1994; **176**: 966–72.
- 15 Llobes R, Cascales E, Walburger A et al. The Tol-Pal proteins of the *Escherichia coli* cell envelope: an energized system required for outer membrane integrity? *Res Microbiol* 2001; **152**: 523–9.
- 16 Carballes F, Bertrand C, Bouche JP et al. Regulation of *Escherichia coli* cell division genes *ftsA* and *ftsZ* by the two-component system *rscC-rscB*. *Mol Microbiol* 1999; **34**: 442–50.
- 17 Ebel W, Vaughn GJ, Peters HK III et al. Inactivation of *mdoH* leads to increased expression of colanic acid capsular polysaccharide in *Escherichia coli*. *J Bacteriol* 1997; **179**: 6858–61.
- 18 Fognini-Lefebvre N, Lazzaroni JC, Portalier R. *tolA*, *tolB* and *excC*, three cistrons involved in the control of pleiotropic release of periplasmic proteins by *Escherichia coli* K12. *Mol Gen Genet* 1987; **209**: 391–5.
- 19 Kennedy EP, Rumley MK. Osmotic regulation of biosynthesis of membrane-derived oligosaccharides in *Escherichia coli*. *J Bacteriol* 1988; **170**: 2457–61.
- 20 Ray MC, Germon P, Vianney A et al. Identification by genetic suppression of *Escherichia coli* TolB residues important for TolB-Pal interaction. *J Bacteriol* 2000; **182**: 821–4.
- 21 Laubacher ME, Ades SE. The Rcs phosphorelay is a cell envelope stress response activated by peptidoglycan stress and contributes to intrinsic antibiotic resistance. *J Bacteriol* 2008; **190**: 2065–74.
- 22 Ballesteros M, Kusano S, Ishihama A et al. The *ftsQ1p* gearbox promoter of *Escherichia coli* is a major sigma S-dependent promoter in the *ddlB-ftsA* region. *Mol Microbiol* 1998; **30**: 419–30.
- 23 Costa CS, Anton DN. Role of the *ftsA1p* promoter in the resistance of mucoid mutants of *Salmonella enterica* to mecillinam: characterization of a new type of mucoid mutant. *FEMS Microbiol Lett* 2001; **200**: 201–5.
- 24 Sitnikov DM, Schineller JB, Baldwin TO. Control of cell division in *Escherichia coli*: regulation of transcription of *ftsQA* involves both *rpoS* and SdiA-mediated autoinduction. *Proc Natl Acad Sci USA* 1996; **93**: 336–41.
- 25 Vinella D, Cashel M, D'Ari R. Selected amplification of the cell division genes *ftsQ-ftsA-ftsZ* in *Escherichia coli*. *Genetics* 2000; **156**: 1483–92.
- 26 Mingorance J, Rivas G, Velez M et al. Strong FtsZ is with the force: mechanisms to constrict bacteria. *Trends Microbiol* 2010; **18**: 348–56.
- 27 Lopez-Montero I, Lopez-Navajas P, Mingorance J et al. Membrane reconstitution of FtsZ-ZipA complex inside giant spherical vesicles made of *E. coli* lipids: large membrane dilation and analysis of membrane plasticity. *Biochim Biophys Acta* 2013; **1828**: 687–98.
- 28 Barbour AG, Mayer LW, Spratt BG. Mecillinam resistance in *Escherichia coli*: dissociation of growth inhibition and morphologic change. *J Infect Dis* 1981; **143**: 114–21.